Noxopharm Ltd.ASX: NOX

SOF-SKN to progress to extension study in CLE patients

· Issued by Noxopharm Ltd. via ASX

Filed with ASX ·

Noxopharm Limited. ABN 50 608 966 123 Suite 71, 159 Ridgecrop Drive, Castle Hill, NSW 2154, Australia SOF-SKN™ to progress to extension study in CLE patients Highlights • Lead clinical asset for the treatment of autoimmune skin diseases to progress to extension clinical study in patients...

View Attachment

6ix hasn’t read this filing yet.

Noxopharm Ltd. on 6ix

Earlier from Noxopharm

Later from Noxopharm

All Noxopharm news releases